Janux Therapeutics (NASDAQ:JANX) Stock Price Down 23.4% – Here’s Why

Posted by Geri Gentry on Nov 11th, 2026

Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report)’s stock price traded down 23.4% during trading on Monday. The company traded as low as $12.43 and last traded at $13.5020. Approximately 567,903 shares traded hands during trading, a decline of 46% from the average daily volume of 1,053,373 shares. The stock had previously closed at $17.63.

Analyst Ratings Changes

JANX has been the subject of a number of analyst reports. Wolfe Research upgraded shares of Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 price target for the company in a research note on Monday, August 24th. Truist Financial lifted their price objective on Janux Therapeutics from $26.00 to $27.00 and gave the company a “buy” rating in a report on Friday, November 6th. TD Cowen raised shares of Janux Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Barclays raised their target price on Janux Therapeutics from $14.00 to $15.00 and gave the company an “underweight” rating in a research note on Friday, November 6th. Finally, HC Wainwright reiterated a “buy” rating on shares of Janux Therapeutics in a research report on Monday, October 19th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $36.92.

Check Out Our Latest Analysis on Janux Therapeutics

Janux Therapeutics Stock Performance

The stock has a market cap of $736.61 million, a price-to-earnings ratio of -7.57 and a beta of 2.44. The business has a 50-day simple moving average of $17.26 and a two-hundred day simple moving average of $15.40.

Janux Therapeutics (NASDAQ:JANX – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.13. The business had revenue of $9.29 million during the quarter, compared to analyst estimates of $8.03 million. On average, analysts expect that Janux Therapeutics, Inc. will post -1.59 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC raised its holdings in Janux Therapeutics by 67.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,642 shares of the company’s stock valued at $28,000 after acquiring an additional 661 shares during the period. Fulcrum Asset Management LLP increased its position in Janux Therapeutics by 3,391.2% during the 3rd quarter. Fulcrum Asset Management LLP now owns 2,374 shares of the company’s stock worth $40,000 after buying an additional 2,306 shares during the period. Versant Capital Management Inc increased its position in Janux Therapeutics by 42.8% during the 2nd quarter. Versant Capital Management Inc now owns 2,615 shares of the company’s stock worth $40,000 after buying an additional 784 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Janux Therapeutics during the third quarter worth $54,000. Finally, Quantbot Technologies LP lifted its holdings in shares of Janux Therapeutics by 2,290.0% during the second quarter. Quantbot Technologies LP now owns 5,497 shares of the company’s stock worth $84,000 after buying an additional 5,267 shares in the last quarter. 75.39% of the stock is currently owned by institutional investors.

About Janux Therapeutics

(Get Free Report)

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for cancer. The company’s research focuses on engaging a patient’s T cells to recognize and attack tumors. Janux’s proprietary platforms are designed to keep certain immune therapies inactive until they reach the tumor environment, with the goal of limiting activity in healthy tissues. Its clinical-stage programs include candidates directed at targets such as PSMA and EGFR, and its broader pipeline includes additional investigational cancer therapies.